Roth Capital Partners initiated coverage of Marker Therapeutics (NASDAQ:MRKR) with a “buy” rating and $10 price target. The stock closed at $5.91 on May 29.
Marker Therapeutics, which was formed from the merger of TapImmune and closely-held Marker Therapeutics, has several ongoing programs in solid and liquid tumors based on its MutiTAA platform (originally from Marker), and its Vaccine platforms (originally from TapImmune).
“Following the merger, it seems to us that the company has directed its primary focus on the MultiTAA program, which has important catalysts during 2019,” writes analyst Tony Butler.
“We believe both platforms hold significant promise, however, given the commercial success of currently-approved CAR-Ts, it may be prudent for investors to closely follow Marker’s MultiTAA T-cell therapy platform,” he added.
Mr. Butler said the MultiTAA platform addresses “several limitations of the current generation of CAR-Ts and should be seen as a strong contender relative to the second generation of CAR-Ts that are currently in the clinic.”
